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AbstrAct
Antiphospholipid syndrome (APS) is a rare disease 
characterised by venous and/or arterial thrombosis, 
pregnancy complications and the presence of specific 
autoantibodies called antiphospholipid antibodies. This 
review aims to identify existing clinical practice guidelines 
(CPG) as part of the eRN ReCONNeT project, aimed at 
evaluating existing CPGs or recommendations in rare 
and complex diseases. Seventeen papers providing 
important data were identified; however, the literature 
search highlighted the scarceness of reliable clinical data 
to develop CPGs. with no formal clinical guidelines in 
place, diagnosis and treatment of APS is largely based on 
consensus and expert opinion. Patients’ unmet need refers 
to the understanding of the disease and its clinical picture 
and implications, the need of education for patients, family 
members and healthcare providers, as well as to the 
development of monitoring pathways involving multiple 
healthcare providers.
InTroduCTIon
Antiphospholipid syndrome (APS) is a 
systemic autoimmune disease with the 
highest prevalence in women of childbearing 
age, characterised by venous and/or arterial 
thrombosis, pregnancy complications and 
the presence of specific autoantibodies called 
antiphospholipid (aPL) antibodies. APS is 
a rare disease; although accurate figures 
for incidence and prevalence are lacking, 
it is generally considered to fall within the 
Orphanet definition of rare disease, being 
a disease not affecting more than 1 person 
per 2000 (https://www. orpha. net/ consor4. 
01/ www/ cgi- bin/ Disease. php? lng= EN). Due 
to its low prevalence, not many randomised, 
controlled clinical trials have been under-
taken. This review aims to identify all existing 
clinical guidelines on APS, to integrate 
possible recommendations and to identify 
unmet needs with regard to diagnosis and 
management of APS. This work has been 
driven by the ERN ReCONNET team that 
performed the literature research and assisted 
the authors during the whole search process. 
In addition, ERN ReCONNET allowed for the 
first time, at least to our knowledge, to write 
a manuscript including both patients and 
physicians’ opinions about the disease and its 
management.
MeThods
We carried out a systematic search in PubMed 
and Embase based on controlled terms 
Key messages 
What is already known about this subject?
 ► Antiphospholipidsyndrome (APS) is a rare systemic 
autoimmune disease characterised by venousand/or 
arterial thrombosis, pregnancy complications and the 
presence ofspecific antiphospholipid autoantibodies.
 ► Thereare still unmet needs with regard to diagnosis 
and management of APS.
What does this study add ?
 ► This review identified all existing clinical practice 
guidelines (CPGs) on APS inorder to integrate possi-
ble recommendations.
how might this impact on clinical practice or 
futuredevelopments?
 ► Theliterature search highlighted the scarceness of 
reliable clinical data todevelop CPGs.
 ► Diagnosisand treatment of APS is largely based on 
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(MeSH and Emtree) and keywords of the disease and 
publication type (clinical practice guidelines (CPG)). 
We reviewed all the published articles in order to identify 
existing CPGs on diagnosis, monitoring and treatment, 
according to the Institute of Medicine 2011 definition 
(CPGs are statements that include recommendations 
intended to optimise patient care that are informed by 
a systematic review of evidence and an assessment of the 
benefits and harms of alternative care options).
The disease coordinator of the ERN ReCONNET for 
APS has assigned the work on CPGs to the healthcare 
providers (HCP) involved. This publication was funded 
by the European Union’s Health Programme (2014-
2020), Framework Partnership Agreement number: 
739531 – ERN ReCONNET. The content of this publi-
cation represents the views of the authors only and it 
is their sole responsibility; it cannot be considered to 
reflect the views of the European Commission and/or 
the Consumers, Health, Agriculture and Food Executive 
Agency (CHAFEA) or any other body of the European 
Union. The European Commission and the Agency do 
not accept any responsibility for use that may be made of 
the information it contains.
Moreover, in order to implement the list of guidelines 
provided by Medline and Embase search, the group 
also performed a hand search. A first screening among 
papers included in the final list (systematic search +hand 
search) was based on title and abstract selected evidence-
based medicine guidelines. A general assessment of the 
CPGs was performed following the Appraisal of Guide-
lines, Research and Evaluation II tool checklist1 not used 
for formal appraisal but rather intended to inform discus-
sion. A discussion group was set for the evaluation of the 
existing CPGs and to identify the unmet needs.
Shown below are the terms used in the search strategy:
Medline (PubMed): (“antiphospholipid 
syndrome”[MeSH Terms] OR (“antiphospholipid”[All 
Fields] AND “syndrome”[All Fields]) OR “antiphos-
pholipid syndrome”[All Fields]) AND (“Practice Guide-
line”[Publication Type] OR “Practice Guidelines As 
Topic”[MeSH Terms] OR Practice Guideline[Publica-
tion Type] OR “Practice Guideline”[Text Word] OR 
“Practice Guidelines”[Text Word] OR “Guideline”[Pub-
lication Type] OR “Guidelines As Topic”[MeSH Terms] 
OR Guideline[Publication Type] OR “Guideline”[Text 
Word] OR “Guidelines”[Text Word] OR “Consensus 
Development Conference”[Publication Type] OR 
“Consensus Development Conferences As Topic”[MeSH 
Terms] OR “Consensus”[MeSH Terms] OR “Consen-
sus”[Text Word] OR “Recommendation”[Text Word] OR 
“Recommendations”[Text Word] OR “Best Practice”[Text 
Word] OR “Best Practices”[Text Word]). Embase: ('anti-
phospholipid syndrome'/exp OR 'Hughes syndrome' 
OR 'antiphospholipid syndrome' OR 'primary antiphos-
pholipid syndrome' OR 'syndrome, antiphospholipid') 
AND ('practice guideline'/exp OR ‘practice guideline’ 
OR ‘practice guidelines’/exp OR ‘practice guidelines’ 
OR 'clinical practice guideline'/exp OR ‘clinical practice 
guideline’ OR ‘clinical practice guidelines’/exp OR ‘clin-
ical practice guidelines’ OR 'clinical practice guidelines 
as topic'/exp OR ‘clinical practice guidelines as topic’ 
OR ‘guideline'/exp OR ‘guideline’ OR ‘guidelines’/exp 
OR ‘guidelines’ OR 'guidelines as topic'/exp OR ‘guide-
lines as topic’ OR ‘consensus development’/exp OR 
‘consensus development’ OR ‘consensus development 
conference’/exp OR ‘consensus development confer-
ence’ OR ‘consensus development conferences’/exp OR 
‘consensus development conferences’ OR ‘consensus 
development conferences as topic’/exp OR ‘consensus 
development conferences as topic’ OR ‘consensus’/exp 
OR ‘consensus’ OR ‘recommendation’ OR ‘recommen-
dations’) AND [embase]/lim NOT [medline]/lim
state of the art on CPGs
By a systematic search, 808 papers were identified 
initially; 25 papers were added by hand search. A total of 
439 papers were selected and screened on full text. Out 
of these, a total of 18 papers2–19 were finally evaluated. 
Among these 18 papers, one paper was excluded from 
the evaluation because this was a report of a task force 
meeting, reflecting expert opinion.17
At this moment, no formal CPGs covering all the 
aspects of diagnosis and treatment of APS could be iden-
tified even if a conventional way to manage these patients, 
mainly experience based, has been identified. However, 
several papers were dealing with important issues and 
unmet needs, which should be included in a future guide-
line. The following paragraphs will summarise where we 
stand and what we still need to do.
unmet needs
Clinicians’ unmet needs
We identified the following areas of uncertainty that 
need to be addressed in a guideline: laboratory tests and 
their standardisation,2–5 primary prophylaxis,6–10 throm-
bosis treatment,3 7–12 pregnancy and pregnancy-related 
issues management,3 7 13–16 non-criteria manifestations17 
and catastrophic APS (CAPS).18 19
The articles that contain information about unmet 
needs are shown in table 1.
Laboratory tests
Although standardised testing for lupus anticoagulant 
(LA), anticardiolipin and anti-beta2GPI antibodies 
remains a concern, both influencing research and clin-
ical diagnosis, clear recommendations on best practices 
for immunoassays for the measurement of aPL (by the 
three tests) and on the most important requirements 
for technical and performance characteristics have been 
published.3 4 Today, the complete antibody profile is 
required for diagnosis and classification of patients with 
APS, and most importantly for the risk assessment of both 
pregnancy morbidity and thrombosis. In fact, patients with 
the so-called ‘triple antibody positivity’, those with LAC 
test positivity or those with high IgG aCL/anti-beta2GPI 
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Table 1 List of the references discussing unmet needs in APS
Unmet needs Articles
Laboratory tests Bertolaccini et al,2 Keeling et al,3 Lakos et al,4 Pengo et al5
Primary prophylaxis Alarcon-Segovia et al,6 Bertsias et al,7 Bertsias et al,8 Groot et al,9* Ruiz-Irastorza et al10
Thrombosis treatment Bertsias et al,7 Bertsias et al,8 Ruiz-Irastorza et al,10 Crowther and Wisloff,11 Keeling et al,3 
Meroni et al,12 Groot et al9
Obstetric complications Keeling et al,3 Bates et al,13 de Jesus et al,14 Huchon et al,15 Andreoli et al,16 Bertsias et al7
Non-criteria manifestations Abreu et al17 (note: negatively graded through AGREE-II tool, no original data but expert 
opinion)
Catastrophic APS Asherson et al,18 Groot et al9*
*Paediatric articles.
AGREE, Appraisal of Guidelines, Research and Evaluation; APS, antiphospholipid syndrome.
IgM aCL/anti-beta2GPI antibodies needs further studies. 
However, evidence that so-called ‘non-criteria’ aPL tests 
may contribute to the diagnosis and risk stratification 
in APS is building up. For instance, antibodies directed 
against domain 1 of beta2GPI were shown to correlate 
with triple positivity and correlate with higher titres of 
aPL.20 21 Furthermore, testing of ‘non-criteria’ antibodies 
such as antiphosphatidylserine and antiphosphatidyl-
serine/prothrombin complex may be helpful in patients 
with clinical symptoms comparable with APS, but without 
positive classical antibodies, so-called seronegative APS. 
Including these non-criteria antibodies may result in a 
better identification of patients with APS.22 However, the 
clinical value of these antibodies remains to be proven.
Primary prophylaxis
Patients with positive aPL, but without clinical symptoms/
events compatible with APS, presumably have a higher 
thrombotic risk profile, in particular patients who tested 
triple positive or have persistently high titres of aPL. How 
to prevent thrombotic events in this group of patients is 
still being debated. It is not clear if low-dose aspirin may 
or may not influence thrombotic risk,23 24 and the use of 
hydroxychloroquine for this purpose showed conflicting 
results.25 26 How to identify who to treat, and consequently 
how to treat, are still unanswered questions.
Thrombosis treatment
The mainstay of treatment of thrombotic APS remains 
vitamin K antagonists, although with recognised limita-
tions especially in the long-term follow-up,27 failing to 
prevent recurrent events. Recommendations on treat-
ment of a first thrombotic event, or a second event while 
on anticoagulation, both for venous and arterial throm-
bosis, have been published.28 However, these recom-
mendations are largely based on expert opinion and 
randomised controlled clinical trials are mostly lacking. 
Although several reports suggest that additional drugs, 
such as hydroxychloroquine, rituximab, intravenous Ig 
and eculizumab, may have a place in the treatment of 
thrombotic APS, their position in clinical practice is not 
well defined.29–32 Direct acting oral anticoagulants for 
treatment of APS were investigated with special interest 
(mainly because of their administration that does not 
need international normalised ratio (INR) monitoring); 
these relatively new drugs are considered first-line 
therapy for atrial fibrillation and deep venous throm-
bosis in many countries. Unfortunately, at least for rivar-
oxaban, the efficacy and safety in patients with APS has 
not been demonstrated.33
In patients with APS, long-term anticoagulant treat-
ment is indicated. Treatment withdrawal has been 
suggested for patients who became antibody negative.19
Obstetric complications
With the introduction of combined low-dose aspirin and 
low molecular weight heparin, most of the aPL-related 
pregnancy loss can be prevented.14
The ‘grading’ of treatment is linked to the clinical and 
serological disease profile (figure 1).
However, severe adverse pregnancy outcomes such as 
pre-eclampsia, low birth weight and early birth, and fetal 
deaths can still occur despite treatment.16 Additional 
treatments with hydroxychloroquine, low-dose predni-
sone and intravenous Ig have been suggested to be bene-
ficial, but further studies are needed to confirm their 
clinical value.34–36 More experimental, pathophysiolog-
ical-based approaches for the prevention of pregnancy 
loss and other pregnancy morbidity in APS are being 
investigated, including the use of statins.37
Based on experience, the use of combined contracep-
tive drugs in patients with APS is linked to an increased 
thrombosis risk and is therefore discouraged. Progestin 
pill is not always well tolerated by the patients. Therefore, 
intrauterine devices (with or without progestin) are actu-
ally recommended.16
Non-criteria manifestations
Though not part of the clinical classification criteria, 
symptoms and signs such as livedo reticularis, skin 
ulcers, sterile endocarditis, migraine, chorea, epilepsy 
and nephropathy are often observed in patients with 
APS. Treatment of these features is a matter of debate 
and based on expert opinion; no conclusive clin-
ical studies on this subject have been performed; 
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Figure 1 Conventional treatment to prevent obstetric complications during pregnancy. *Antiphospholipid (aPL) antibody 
carriers: individuals with aPL positivity without any anamnestic thrombotic event or pregnancy complications. #Low-risk aPL 
profile: single aPL positivity OR double positivity but low aPL titre OR IgM isotype. §High-risk aPL profile: triple aPL positivity 
OR LA positivity OR high-titre aCL and anti-B2GPI IgG/IgM. °Additional risk factors: risk factors for thrombosis other than aPL; 
autoimmune diseases such as systemic lupus erythematosus. Hydroxychloroquine can be added when indicated (ie, systemic 
lupus or autoimmunity features).
immunosuppressive treatments with or without low-dose 
aspirin and warfarin.19 38
Catastrophic APS
CAPS is a rare but very severe form of APS, characterised 
by multiorgan failure due to massive small vessel throm-
bosis, occurring in an estimated <1% of patients with 
APS. Data from the international CAPS registry show that 
treatment with a combination of heparin, corticoster-
oids, plasma exchange and/or intravenous Ig and, some-
times, rituximab or eculizumab, results in higher survival 
rates.39 A proposed algorithm of treatment is provided in 
figure 2. However, these data are based on a retrospective 
case series, subjected to inclusion bias. Due to the severity 
and rarety of the disease, no prospective studies on treat-
ment of CAPS have been undertaken. Complement inhi-
bition may be of added value in the treatment of CAPS, 
but its position is not well established yet.40 The recently 
published international guidelines are largely based on 
expert opinion.41
Patients’ unmet needs
On diagnosis of APS there are two reactions the patient 
experiences: ‘dismay’ and ‘surprise’.
Regarding ‘surprise’, women of childbearing age 
should know about the pathology and its possible compli-
cations, without alarmism. Non-immunologists should 
also understand APS and its symptoms: it is difficult to 
diagnose rapidly and the patient can suffer multiple 
traumatic events (such as multiple miscarriages), which 
might otherwise be avoided. It is also difficult for patients 
to identify suitable specialists, as the symptoms are not 
always easily interpretable. Again, this could be addressed 
through more widespread knowledge of the disease. On 
confirmation of diagnosis it is important for the patient 
and family to understand the disease’s possible effects 
and the purpose of each drug. This information would 
engage the patient and family in treatment, rather than 
‘imposing it from above’ and would help affront lengthy 
and complex treatment, which is a burden on the patient. 
The treatment should be tailored to the person, after 
careful study of the clinical history.
Regarding ‘dismay’, a ‘network’ must be created 
between specialist, general practitioner, family, friends 
and coworkers, as solitude can be a great obstacle in 
dealing with the pathology, its possible effects and the 
need for treatment. The effects of APS also often have 
a negative impact on the patient’s life: the resulting 
events, as well as the time and the energy consumed by 
the pathology, commonly delay career advancement or 
building a family. It can even be difficult to withstand 
the financial burden (eg, for specialist consultancies, 
for INR home measurement systems), especially without 
structured support from a public health service. Lastly, 
doctors could be more encouraging towards patients 
with APS: discouraging people from having children or 
creating anxiety regarding possible complications helps 
neither the patient nor research. Despite a ‘difficult’ 
clinical picture, the positive results obtained can often 
surprise doctors as well as the patient himself.
ConClusIons
With APS being a rare disease, not many well-designed 
clinical trials have been performed, resulting in a lack of 
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Figure 2 Proposed algorithm for treatment of CAPS. CAPS, 
catastrophic antiphospholipid syndrome; INR, international 
normalised ratio. (Modified from Cervera et al39).
in place, diagnosis and treatment of APS is largely based 
on consensus and expert opinion.
In the current review process, we were able to identify 
six main areas of uncertainty for patient’s diagnosis and 
care, namely: laboratory tests and their standardisation, 
primary prophylaxis, thrombosis treatment, pregnancy 
and pregnancy-related issues management, non-criteria 
manifestations and CAPS. The 17 papers evaluated allo-
cated to the respective areas could be useful in providing 
background information for a future clinical guideline. 
However, some limitations concerning these papers 
were noted. First, some papers had a primary focus on 
systemic lupus erythematosus, including only scarce 
data and recommendations on APS. Second, most of 
the included papers were rather outdated, with only six 
articles published in the last 3 years, while others were 
published 5–9 years and one 14 years ago.
In conclusion, we were able to identify 17 papers that 
provide important and helpful data on APS that should 
be taken into account for the development of a future 
clinical guideline. However, much more well-designed 
clinical research is needed to answer the still many open 
questions in this disease. Patients’ unmet needs deserve 
special interest in future research. At present, the Euro-
pean League Against Rheumatism installed a task force, 
working on a clinical guideline for the management of 
APS. Large international collaborations will be necessary 
to have enough statistical power in future studies.
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